“After hearing about the innovative and important work that Brian Trust Bio was doing in ALS research, we were excited to join forces and collaborate with their team on the validation of mutations that cause a spontaneous form of ALS. Their approach to addressing the genetic causes of sporadic ALS, and possibly identifying individualized treatments that could move into clinical trials to benefit a larger ALS population is at the cutting edge of personalized medicine. Icagen is dedicated to changing the outcomes for patients with rare CNS diseases by advancing therapeutic programs and the collaboration with Brian Trust Bio moves us that much closer to achieving our objectives.”
